Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 22, 2026, 12:35 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 169–192 of 781 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Bloodstream Infection Clear all
Completed Phase 2 Interventional Results available

Effects of the V1a Agonist FE 202158 in Patients With Septic Shock

NCT01000649
View directory record Official record
Conditions
Septic Shock
Interventions
FE 202158 1.25, FE 202158 2.5, FE 202158 3.75, Placebo
Drug · Other
Lead sponsor
Ferring Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
6
States / cities
Newark, Delaware • Springfield, Massachusetts • Duluth, Minnesota + 3 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2017 · Synced Oct 22, 2026, 12:35 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Phase I STEBVax in Healthy Adults

NCT00974935
View directory record Official record
Conditions
Toxic Shock Syndrome Staphylococcal
Interventions
Aluminum hydroxide, STEBVax vaccine
Drug · Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 40 Years
Enrollment
29 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2015
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 19, 2015 · Synced Oct 22, 2026, 12:35 AM EDT
Terminated No phase listed Observational

Study of Periodontitis and Blood Stream Infection in AML Patients Receiving Chemotherapy

NCT04858594
View directory record Official record
Conditions
Acute Myeloid Leukemia
Interventions
Planned Chemotherapy
Other
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 11, 2022 · Synced Oct 22, 2026, 12:35 AM EDT
Completed Phase 2 Interventional

Safety and Efficacy of ART-123 in Subjects With Sepsis and Disseminated Intravascular Coagulation

NCT00487656
View directory record Official record
Conditions
Sepsis, Disseminated Intravascular Coagulation
Interventions
ART-123, placebo
Drug
Lead sponsor
Artisan Pharma, Inc.
Industry
Eligibility
18 Years and older
Enrollment
750 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
49
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tuscon, Arizona + 46 more
Source: ClinicalTrials.gov public record
Updated May 18, 2011 · Synced Oct 22, 2026, 12:35 AM EDT
Completed Phase 2 Interventional Results available

Acetaminophen and Ascorbate in Sepsis: Targeted Therapy to Enhance Recovery

NCT04291508
View directory record Official record
Conditions
Acute Respiratory Distress Syndrome, Critical Illness, Respiratory Failure, Sepsis
Interventions
Intravenous Acetaminophen (room temperature), Intravenous Vitamin C (refrigerated), 5% Dextrose (room temperature), 5% Dextrose refrigerated
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
488 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
41
States / cities
Birmingham, Alabama • Tucson, Arizona • Fresno, California + 34 more
Source: ClinicalTrials.gov public record
Updated Sep 27, 2024 · Synced Oct 22, 2026, 12:35 AM EDT
Not listed Phase 4 Interventional

Effect of Biktarvy & Symtuza on microRNAs in HIV and Correlation With Weight Gain

NCT05463783
View directory record Official record
Conditions
HIV Infections, Obesity
Interventions
Biktarvy, Symtuza
Drug
Lead sponsor
East Carolina University
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Greenville, North Carolina
Source: ClinicalTrials.gov public record
Updated Nov 14, 2023 · Synced Oct 22, 2026, 12:35 AM EDT
Not listed No phase listed Observational

Discharge Readmission Analysis and Management in Sepsis (DReAMS-2)

NCT06099756
View directory record Official record
Conditions
Sepsis
Interventions
Not listed
Lead sponsor
Measure Labs, Inc.
Industry
Eligibility
18 Years to 100 Years
Enrollment
2,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
3
States / cities
Durham, North Carolina • Raleigh, North Carolina
Source: ClinicalTrials.gov public record
Updated Nov 7, 2023 · Synced Oct 22, 2026, 12:35 AM EDT
Completed Phase 2 Interventional

A Safety and Efficacy Study of Intravenous E5564 in Patients With Severe Sepsis

NCT00046072
View directory record Official record
Conditions
Sepsis, Shock, Septic, Sepsis Syndrome, Septicemia, Infection
Interventions
E5564
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
18 Years to 85 Years
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2005
U.S. locations
17
States / cities
Mobile, Alabama • San Diego, California • Santa Barbara, California + 14 more
Source: ClinicalTrials.gov public record
Updated Dec 12, 2005 · Synced Oct 22, 2026, 12:35 AM EDT
Terminated Phase 1 Interventional

L-Carnitine Administration in Early Sepsis

NCT01193777
View directory record Official record
Conditions
Septic Shock
Interventions
L-Carnitine, Normal Saline
Drug
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
2
States / cities
Jackson, Mississippi • Charlotte, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 22, 2022 · Synced Oct 22, 2026, 12:35 AM EDT
Completed Phase 4 Interventional Results available

Ketamine Versus Etomidate for Rapid Sequence Intubation

NCT01823328
View directory record Official record
Conditions
Airway Control, Anesthesia, Intubation, Complication
Interventions
Ketamine, Etomidate
Drug
Lead sponsor
Hennepin Healthcare Research Institute
Other
Eligibility
18 Years and older
Enrollment
143 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated May 24, 2019 · Synced Oct 22, 2026, 12:35 AM EDT
Completed Not applicable Interventional

Improving Morbidity During Post-Acute Care Transitions for Sepsis

NCT03865602
View directory record Official record
Conditions
Clinical Sepsis
Interventions
Sepsis Transition And Recovery (STAR), Usual care
Behavioral
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older
Enrollment
712 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Charlotte, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 25, 2022 · Synced Oct 22, 2026, 12:35 AM EDT
Completed Phase 1 Interventional

Effects of Endotoxin in Normal Human Volunteers

NCT00001303
View directory record Official record
Conditions
Healthy, Lung Disease, Sepsis, Septic Shock
Interventions
Reference Endotoxin, Inhaled Nitric Oxide
Drug
Lead sponsor
National Institutes of Health Clinical Center (CC)
NIH
Eligibility
18 Years to 45 Years
Enrollment
198 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1992 – 2018
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 5, 2018 · Synced Oct 22, 2026, 12:35 AM EDT
Completed No phase listed Observational

Sepsis Post Market Observational Study and Potential Reduction of Time to Antibiotics - Washington University

NCT04353388
View directory record Official record
Conditions
Sepsis, Adult Disease, Severe Sepsis, Emergency Department
Interventions
CBC-DIFF Monocyte Volume Width Distribution (MDW)
Diagnostic Test
Lead sponsor
Beckman Coulter, Inc.
Industry
Eligibility
18 Years to 89 Years
Enrollment
1,139 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Mar 17, 2021 · Synced Oct 22, 2026, 12:35 AM EDT
Completed No phase listed Observational

The Impact of Chlorhexidine-Based Bathing on Nosocomial Infections

NCT00448942
View directory record Official record
Conditions
Nosocomial Bacteremia, Nosocomial Fungemia, MRSA Colonization, MRSA Infection, VRE Colonization, VRE Infection
Interventions
Daily bathing with Chlorhexidine based product
Behavioral
Lead sponsor
Hunter Holmes Mcguire Veteran Affairs Medical Center
Federal
Eligibility
18 Years and older
Enrollment
5,300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
4
States / cities
Baltimore, Maryland • St Louis, Missouri • New York, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 19, 2007 · Synced Oct 22, 2026, 12:35 AM EDT
Completed Phase 3 Interventional Results available

Phase 3 Safety and Efficacy Study of ART-123 in Subjects With Severe Sepsis and Coagulopathy

NCT01598831
View directory record Official record
Conditions
Severe Sepsis, Coagulopathy
Interventions
ART-123, Placebo
Drug
Lead sponsor
Asahi Kasei Pharma America Corporation
Industry
Eligibility
18 Years and older
Enrollment
816 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2019
U.S. locations
22
States / cities
Mobile, Alabama • Phoenix, Arizona • Atlanta, Georgia + 17 more
Source: ClinicalTrials.gov public record
Updated Apr 21, 2020 · Synced Oct 22, 2026, 12:35 AM EDT
Not yet recruiting No phase listed Observational

TDAP in Burn Patients (Group 2)

NCT07223684
View directory record Official record
Conditions
Sepsis, Burn Injury, Wound Healing, Critical Illness, Multiple Organ Dysfunction Syndrome
Interventions
Observational Cohort (No Intervention)
Other
Lead sponsor
Henry M. Jackson Foundation for the Advancement of Military Medicine
Other
Eligibility
18 Years to 80 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
3
States / cities
Tampa, Florida • Atlanta, Georgia • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 4, 2026 · Synced Oct 22, 2026, 12:35 AM EDT
Completed Phase 1 Interventional

Study of Mycamine® in Infants and Toddlers With Fungal Infections to Evaluate Safety and Blood Levels of the Drug

NCT00607763
View directory record Official record
Conditions
Invasive Candidiasis, Esophageal Candidiasis, Oropharyngeal Candidiasis, Candidemia
Interventions
Micafungin (Mycamine)
Drug
Lead sponsor
Astellas Pharma Inc
Industry
Eligibility
4 Months to 23 Months
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
6
States / cities
Los Angeles, California • Orange, California • Louisville, Kentucky + 3 more
Source: ClinicalTrials.gov public record
Updated Aug 20, 2014 · Synced Oct 22, 2026, 12:35 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Pharmacokinetic and Biomarker Study of Pioglitazone in Adolescents With Severe Sepsis and Septic Shock

NCT01352182
View directory record Official record
Conditions
Severe Sepsis, Septic Shock
Interventions
Pioglitazone hydrochloride
Drug
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
Not listed
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2017
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 2, 2020 · Synced Oct 22, 2026, 12:35 AM EDT
Completed No phase listed Observational Results available

Inflammatory Cytokine Quantification in Infants

NCT01155830
View directory record Official record
Conditions
Sepsis, Congenital Diaphragmatic Hernia, Neonatal Cardiopulmonary Failure
Interventions
Not listed
Lead sponsor
University of Utah
Other
Eligibility
Up to 2 Months
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
2
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated May 4, 2015 · Synced Oct 22, 2026, 12:35 AM EDT
Recruiting Not applicable Interventional

Evaluation of Pediatric eCART Implementation

NCT06771830
View directory record Official record
Conditions
Pediatric ALL, Sepsis
Interventions
Pediatric eCART
Device
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
Up to 17 Years
Enrollment
30,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Aug 13, 2026 · Synced Oct 22, 2026, 12:35 AM EDT
Completed Not applicable Interventional

HeRO Vascular Access Device Bacteremia Study

NCT00889564
View directory record Official record
Conditions
Hemodialysis
Interventions
HeRO Vascular Access Device
Device
Lead sponsor
Merit Medical Systems, Inc.
Industry
Eligibility
18 Years and older
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
7
States / cities
Miami, Florida • Atlanta, Georgia • Springfield, Illinois + 4 more
Source: ClinicalTrials.gov public record
Updated Aug 8, 2017 · Synced Oct 22, 2026, 12:35 AM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

Detoxified J5 Core Glycolipid/ Group B Meningococcal Outer Membrane Protein Vaccine for Gram-negative Bacterial Sepsis Administered With and Without Synthetic CPG Oligodeoxynucleotide 7909 Adjuvant

NCT01164514
View directory record Official record
Conditions
Bacterial Sepsis
Interventions
CPG 7909, J5-OMP Vaccine, Placebo
Biological · Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 50 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2013
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 31, 2014 · Synced Oct 22, 2026, 12:35 AM EDT
Completed No phase listed Observational

Clinical Outcomes and Cost of Gram Negative Bacteremia

NCT02599220
View directory record Official record
Conditions
Gram-negative Bacteremia, Bacteremia
Interventions
Not listed
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
2,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2015
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Nov 6, 2015 · Synced Oct 22, 2026, 12:35 AM EDT
Completed Phase 3 Interventional

A Prospective, Randomized, Phase III Trial of FLAC (5-Fluorouracil, Leucovorin, Adriamycin, Cytoxan) Chemotherapy With GM-CSF (Granulocyte-Macrophage Colony-Stimulating Factor) Versus PIXY 321 in Advanced Breast Cancer

NCT00001338
View directory record Official record
Conditions
Breast Neoplasms, Fever, Hematologic Diseases, Neutropenia, Sepsis
Interventions
FLAC chemotherapy with GM-CSF
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Not listed
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1993 – 2001
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Oct 22, 2026, 12:35 AM EDT